BioNTech SE
BNTX
$107.34
-$0.16-0.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.97B | 2.98B | 3.30B | 2.91B | 2.95B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.97B | 2.98B | 3.30B | 2.91B | 2.95B |
| Cost of Revenue | 608.79M | 584.76M | 518.02M | 497.44M | 610.40M |
| Gross Profit | 2.36B | 2.39B | 2.78B | 2.41B | 2.34B |
| SG&A Expenses | 631.01M | 648.05M | 660.43M | 662.05M | 614.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 652.17M | 698.51M | 193.20M | -152.88M | -454.03M |
| Total Operating Expenses | 4.33B | 4.37B | 3.78B | 3.35B | 2.89B |
| Operating Income | -1.36B | -1.39B | -475.90M | -441.84M | 60.88M |
| Income Before Tax | -840.49M | -731.97M | -339.05M | -266.01M | 152.62M |
| Income Tax Expenses | -27.86M | -14.84M | 161.73M | 277.75M | 34.17M |
| Earnings from Continuing Operations | -812.62 | -717.13 | -500.78 | -543.77 | 118.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -812.62M | -717.13M | -500.78M | -543.77M | 118.45M |
| EBIT | -1.36B | -1.39B | -475.90M | -441.84M | 60.88M |
| EBITDA | -1.09B | -1.12B | -295.63M | -265.43M | 218.31M |
| EPS Basic | -3.38 | -2.99 | -2.08 | -2.25 | 0.50 |
| Normalized Basic EPS | -1.86 | -1.58 | -0.60 | -0.51 | 0.53 |
| EPS Diluted | -3.40 | -3.00 | -2.11 | -2.28 | 0.48 |
| Normalized Diluted EPS | -1.86 | -1.59 | -0.62 | -0.53 | 0.51 |
| Average Basic Shares Outstanding | 962.63M | 962.81M | 962.27M | 960.39M | 960.99M |
| Average Diluted Shares Outstanding | 965.61M | 965.80M | 966.52M | 965.28M | 965.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |